RxDoctor Payments Data

Obinna Oriaku

Internal Medicine · Charlotte, NCNPI 1962424689

Payments from drug & device makers

$422in general payments, 2019–2025

Across 17 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$133
  • Novartis$98
  • Pfizer$67
  • Sanofi Pasteur Inc.$25
  • Avanir Pharmaceuticals, Inc.$22
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$20
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$41699%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422 in reported general payments places this provider in the 60th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$47,180
Medicare patients
172
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide11$10,138
EliquisApixaban13$7,646
Valsartan14$216
Gabapentin11$211
Amlodipine Besylate43$195
Montelukast Sodium18$181
Atorvastatin Calcium27$158
Carvedilol29$104
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$102
Pantoprazole Sodium12$89
Trazodone Hcl16$78
Omeprazole16$72
Simvastatin12$68
Metformin Hcl12$62
Clonidine Hcl12$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$7,64613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →